Skip to main content
Premium Trial:

Request an Annual Quote

Investment Bank Downgrades Orchid Stock After Firm Cut 05 Revenue Projection

NEW YORK, March 10 (GenomeWeb News) - Investment bank Caris & Company downgraded Orchid Cellmark stock to "average" from "above average" yesterday after the company cut its 2005 revenue projections.

 

Orchid cut its 2005 total revenue forecast to between $61 million and $62 million from about $64 million, primarily due to lower-than-expected production capacity in its Dallasfacility.

 

The company also said yesterday it has replaced its CEO.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.